AnaptysBio, Inc. (NASDAQ:ANAB) Director Hollings Renton Sells 1,950 Shares

AnaptysBio, Inc. (NASDAQ:ANABGet Free Report) Director Hollings Renton sold 1,950 shares of the firm’s stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $23.16, for a total value of $45,162.00. Following the completion of the sale, the director now directly owns 1,950 shares of the company’s stock, valued at approximately $45,162. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

AnaptysBio Price Performance

NASDAQ ANAB opened at $22.89 on Friday. The stock has a market capitalization of $625.35 million, a PE ratio of -3.73 and a beta of -0.33. AnaptysBio, Inc. has a 12-month low of $13.36 and a 12-month high of $27.50. The company has a 50 day moving average price of $23.47 and a two-hundred day moving average price of $22.79.

AnaptysBio (NASDAQ:ANABGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.10). AnaptysBio had a negative net margin of 711.17% and a negative return on equity of 161.40%. The business had revenue of $7.18 million for the quarter, compared to the consensus estimate of $4.55 million. As a group, equities analysts anticipate that AnaptysBio, Inc. will post -6.04 EPS for the current year.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in shares of AnaptysBio during the 1st quarter worth about $222,000. Jacobs Levy Equity Management Inc. lifted its holdings in AnaptysBio by 38.6% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 49,389 shares of the biotechnology company’s stock worth $1,112,000 after purchasing an additional 13,764 shares during the last quarter. StemPoint Capital LP lifted its holdings in AnaptysBio by 499.0% in the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after purchasing an additional 224,548 shares during the last quarter. Platinum Investment Management Ltd. bought a new stake in AnaptysBio during the first quarter worth approximately $1,490,000. Finally, Acadian Asset Management LLC acquired a new position in AnaptysBio during the first quarter valued at approximately $420,000.

Analyst Ratings Changes

Several brokerages recently issued reports on ANAB. Leerink Partnrs reissued an “outperform” rating on shares of AnaptysBio in a research note on Tuesday, April 16th. BTIG Research started coverage on shares of AnaptysBio in a research report on Monday, February 26th. They issued a “buy” rating and a $55.00 price target for the company. Wells Fargo & Company started coverage on shares of AnaptysBio in a report on Thursday, April 11th. They set an “overweight” rating and a $56.00 price target for the company. SVB Leerink began coverage on shares of AnaptysBio in a research note on Tuesday, April 16th. They issued an “outperform” rating and a $47.00 price objective on the stock. Finally, JPMorgan Chase & Co. decreased their target price on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Monday, April 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, AnaptysBio presently has an average rating of “Moderate Buy” and a consensus target price of $46.38.

Read Our Latest Stock Report on AnaptysBio

About AnaptysBio

(Get Free Report)

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

Featured Articles

Insider Buying and Selling by Quarter for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.